Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
July 13, 2020 16:01 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., July 13, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq:RVMD), a clinical-stage oncology company focused on developing targeted therapies to inhibit elusive...
Revolution Medicines Announces Pricing of $156.0 Million Public Offering of Common Stock
July 08, 2020 22:48 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., July 08, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq:RVMD) today announced the pricing of its underwritten public offering of 6,000,000 shares of common stock...
Revolution Medicines Announces Proposed Public Offering of Common Stock
July 06, 2020 16:01 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., July 06, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq:RVMD) today announced that it has commenced an underwritten public offering of 5,500,000 shares of common...
Revolution Medicines Reports New Application of Tri-Complex Modality for “Undruggable” Protein Targets and Announces License to Ginkgo Bioworks to Explore Potential Use Against Novel Coronavirus
June 30, 2020 16:05 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif. and BOSTON, June 30, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on developing targeted therapies to inhibit...
Revolution Medicines Announces Dosing of First Patient in Clinical Study of RMC-4630 (SAR442720) Combined with PD-1 Inhibitor
June 22, 2020 07:30 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., June 22, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on developing targeted therapies to inhibit frontier...
Revolution Medicines Appoints Eric T. Schmidt, Ph.D. and Peter Svennilson to its Board of Directors
June 18, 2020 07:30 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., June 18, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on developing targeted therapies to inhibit frontier...
Revolution Medicines Reports First Quarter 2020 Financial Results and Continued Corporate Progress
May 14, 2020 16:05 ET
|
Revolution Medicines, Inc.
Closed Initial Public Offering Raising Gross Proceeds of $273.7 Million Presented First Evidence of Clinical Activity of SHP2 Inhibitor (RMC-4630) Against KRAS Mutant Lung Cancers Preclinical...